All You Need to Know About Montes Archimedes Acquisition (ROIV) Rating Upgrade to BuyZacks Investment Research • 02/14/25
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 02/10/25
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business UpdateGlobeNewsWire • 02/10/25
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)Seeking Alpha • 02/05/25
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch CareGlobeNewsWire • 02/03/25
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025GlobeNewsWire • 01/29/25
Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and DevelopmentBusiness Wire • 01/13/25
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 11/12/24
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024GlobeNewsWire • 10/29/24
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%Business Wire • 09/18/24
Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?Zacks Investment Research • 09/10/24
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) ActivatorGlobeNewsWire • 09/10/24
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society CongressGlobeNewsWire • 09/10/24